Compare Blackstone Inc (BX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs ResMed Inc. — how do they compare? Blackstone Inc trades at $144.92 (market cap $117.44B), while ResMed Inc. trades at $223.89 (market cap $32.61B). The key difference: Blackstone Inc is far larger — about 3.6× ResMed Inc.'s market cap, and Blackstone Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| BX | RMD | |
|---|---|---|
Market Cap | $117.44B | $32.61B |
Sector | Financials | Health |
52-Week High | $188.68 | $293.73 |
52-Week Low | $102.12 | $182.82 |
Dividend Yield | 3.55% | 1.17% |
Enterprise Value | — | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $141.67, up 3.31% today, near its consensus price target of $144.00. The stock shows strong bullish technical signals and has consistently beaten earnings estimates in recent quarters. Recent news highlights strategic acquisitions, including a stake in Air Canada's Aeroplan program and a $25.3 billion Australian home loan portfolio purchase from HSBC, signaling aggressive growth and diversification.
Outlook remains positive with robust revenue growth and high profitability, though elevated valuation ratios and overbought RSI levels suggest near-term caution. Key risks include market volatility and integration challenges from recent deals. Analyst consensus is strongly bullish, supporting a favorable long-term view.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
